Literature DB >> 7093094

Alternatives to beta-blockade in therapy of hypertension with angina pectoris: role of nifedipine or of labetalol.

L H Opie, D White, J Lee, W F Lubbe.   

Abstract

1 Patients with combined hypertension and angina pectoris may represent a therapeutic dilemma, with the angina being refractory to conventional beta-blockade. 2 The added benefit of peripheral vasodilation in control of blood pressure is documented in the case of nifedipine. 3 Improved blood pressure control by added nifedipine may not be accompanied by decreased severity of angina pectoris, emphasizing the complex causation of the angina in such patients. 4 The clinically proven added alpha-blocking activity of labetalol distinguishes labetalol from other beta-blockers. However, the suggested benefits of the added alpha-activity in patients with hypertension and angina remain to be proven by further trials in patients.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7093094      PMCID： PMC1401829          DOI： 10.1111/j.1365-2125.1982.tb01899.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  26 in total

1.  Assessment of alpha- and beta-adrenoceptor blocking actions of labetalol.

Authors:  D A Richards; J Tuckman; B N Prichard
Journal:  Br J Clin Pharmacol       Date:  1976-10       Impact factor: 4.335

2.  Simultaneous assessment of effects of coronary vasodilators on the coronary blood flow and the myocardial contractility by using the blood-perfused canine papillary muscle.

Authors:  N Himori; H Ono; N Taira
Journal:  Jpn J Pharmacol       Date:  1976-08

3.  Differences in the mechanisms of borderline and permanent hypertension.

Authors:  M E Safar; Y A Weiss; G M London; N P Chau
Journal:  Postgrad Med J       Date:  1977       Impact factor: 2.401

4.  Alpha-adrenoceptor-mediated coronary artery spasm.

Authors:  D L Levene; M R Freeman
Journal:  JAMA       Date:  1976-08-30       Impact factor: 56.272

5.  Blood-pressure and catecholamine excretion after mental stress in labile hypertension.

Authors:  P J Nestel
Journal:  Lancet       Date:  1969-04-05       Impact factor: 79.321

6.  Mortality and coronary heart disease among men studied for 23 years.

Authors:  Ancel Keys; Henry Longstreet Taylor; Henry Blackburn; Josef Brozek; Joseph T Anderson; Ernst Simonson
Journal:  Arch Intern Med       Date:  1971-08

7.  Hemodynamic effects of labetalol, an alpha and beta adrenergic blocking agent, in hypertensive subjects.

Authors:  J Mehta; J N Cohn
Journal:  Circulation       Date:  1977-02       Impact factor: 29.690

8.  Pharmacological basis for antihypertensive effects of intravenous labetalol.

Authors:  D A Richards; B N Prichard; A J Boakes; J Tuckman; E J Knight
Journal:  Br Heart J       Date:  1977-01

9.  Studies on the pharmacokinetics and pharmacodynamics of atenolol in man.

Authors:  J D Fitzgerald; R Ruffin; K G Smedstad; R Roberts; J McAinsh
Journal:  Eur J Clin Pharmacol       Date:  1978-05-17       Impact factor: 2.953

10.  Effect of blood pressure angiotensin II and aldosterone concentrations during treatment of severe hypertension with intravenous labetalol: comparison with propranolol.

Authors:  P M Trust; E A Rosei; J J Brown; R Fraser; A F Lever; J J Morton; J I Robertson
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335
View more
  3 in total

Review 1.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

2.  Labetalol: the nineteen-eighties.

Authors:  J I Robertson
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

Review 3.  Labetalol in normotensive patients with angina pectoris.

Authors:  K Fox; A A Quyyumi
Journal:  Cardiovasc Drugs Ther       Date:  1988-09       Impact factor: 3.727
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.